Acumen pharmaceuticals to host virtual r&d day on oct. 2, 2024

Newton, mass., sept. 25, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today announced that the company will host a virtual r&d day on wednesday, oct. 2 at 10:00 a.m. et. the webcast will highlight acumen's strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early ad.
ABOS Ratings Summary
ABOS Quant Ranking